Precision BioSciences, Inc. (NASDAQ:DTIL) stock is up during Wednesday’s premarket session, trading higher by 10.55% as the company is announcing new clinical data from its PBGENE-HBV program.

The recent surge in Precision BioSciences’ stock price follows the announcement of new biopsy data demonstrating that PBGENE-HBV effectively eliminates cccDNA, leading to a 10-fold reduction in cccDNA-derived transcripts.

The data also revealed that 100% of patients with detectable pgRNA at baseline achieved pgRNA loss, highlighting the program’s potential in treating chronic hepatitis B.

Technical Analysis

Over the past 12 months, Precision BioSciences has gained 55.01%, reflecting a strong upward trend.

Currently, the stock is trading at $8.38, which positions it 12.2% above its 20-day simple moving average (SMA) of $7.45 and 19.4% above its 50-day SMA of $7.00. The 100-day and 200-day SMAs are at $5.59 and $5.49, respectively, indicating that the stock is significantly above these longer-term averages as well.

The 20-day exponential moving average (EMA) is at $7.36, and the 50-day EMA is at $6.86, further supporting the bullish momentum. The Relative Strength Index (RSI) currently sits at 54.88, indicating a neutral momentum, suggesting that the stock is neither overbought nor oversold at this time.

  • Key Resistance: $8.82 — This level is significant as it represents the 52-week high, which the stock may test if the current momentum continues.
  • Key Support: $7.45 — This level is important as it aligns with the 20-day SMA, providing a potential floor for the stock’s price.

Earnings & Analyst Outlook

Looking further out, the next major catalyst for the stock arrives with the August 6, 2026 (estimated) earnings report.

  • EPS Estimate: Loss of 58 cents (Up from $-2.13)
  • Revenue Estimate: $2.06 million (Up from $18,000)

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $30.00. Recent analyst moves include:

  • Jones Trading: Buy (Target $30.00) (April 17)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Precision BioSciences, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Bullish (Score: 92.66) — Stock is outperforming the broader market.

The Verdict: Precision BioSciences’ Benzinga Edge signal reveals a strong momentum-driven story, indicating that the stock is currently performing well relative to the market. Investors should monitor upcoming developments closely as the company continues to advance its innovative therapies.

Price Action

DTIL Stock Price Activity: Precision BioSciences shares were up 10.55% at $8.38 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock